Design of Experiments
Design of Experiments
QbD
DoE DoE
Levels Value assigned to factor is termed as Level
DoE DoE
Experimental
Domain
Design Space
Experinmental Plan for 23 Factorial Design Experinmental Plan for 23 Factorial Design
Experiment MCC EC mg / tab PVP K-30 Drug Release %
No. mg / tab mg / tab
Main Effect 2 Factor Interaction 3 Factor Interaction
1 80 5 3 80
Experiments Notation X1 X2 X3 X1 X2 X2 X3 X1X3 X1 X2 X3 Drug
Release 78
2 100 5 3
(%)
1 (Null) (-1,-1,-1) -1 -1 -1 +1 +1 +1 -1 80
3 80 10 3 65
2(X1) (+1,-1,-1) +1 -1 -1 -1 +1 -1 +1 78
3(X2) (-1,+1,-1) -1 +1 -1 -1 -1 +1 +1 65
4(X3) (-1,-1,+1) -1 -1 +1 +1 -1 -1 -1 64 4 100 10 3 64
5(X1X2) (+1,+1,-1) +1 +1 -1 +1 -1 -1 +1 72
6(X1X3) (+1,-1,+1) +1 -1 +1 -1 -1 +1 -1 71 5 80 5 5 72
7(X2X3) (-1,+1,+1) -1 +1 +1 -1 +1 -1 -1 62
8(X1X2X3) (+1,+1,+1) +1 +1 +1 +1 +1 +1 +1 60 71
6 100 5 5
7 80 10 5 62
Effect of factor X1 =(78+72+71+60)/4-(80+65+64+62)/4
8 100 10 5 60
= 6 8 . 2 5 - 6 9 . 7 5 = -1.5
DoE Methodologies: Fractional Factorial Design DoE Methodologies: Fractional Factorial Design
DoE Methodologies: Fractional Factorial Design DoE Methodologies: Fractional Factorial Design
DoE Methodologies: Fractional Factorial Design DoE Methodologies: Fractional Factorial Design
Experimental Number of Factors
Runs 2 3 4 5 6 7
4 2 23-1
(Res III)
8 23 24-1 25-2 26-3 27-4
(Res IV) (Res III) (Res III) (Res III)
16 24 25-1 26-2 27-3
(Res V) (Res IV) (Res IV)
32 25 26-1 27-2
(Res V) (Res IV)
Resolution IV Design: no main effect; two factor interaction confounded with two factor
interaction.
Resolution V Design: no main effect and no two factor vs two factor while
two factor confounded with three factor interaction.
Plackett-Burman Design
• Two level fractional factorial
design/Hadamard design
• Preliminary used for screening purpose
• The number of experiments is multiple
of four i.e. 12, 16, 20, 24 The main effect is orthogonal.
Two factor interaction are
• The total number of experiment will be partially confounded. (Differ
will be one more than factor and is from Resolution III)
expressed as N= K+1
Where, N is number of experimental run
and K is the number of factor
QbD does not equal design of experiments (DoE), but the Design expert Stavex Multi simplex
latter could be an important component of QbD. Statistica DoE Wisdom
DRUG
PRODUCT
1.6
Dissolution (%)
1.2
85.0-90.0
70.0
1 80.0-85.0
65.0
60.0 75.0-80.0
0.8
55.0 70.0-75.0
Design Space 0.6
50.0 (linear ranges) 65.0-70.0
40
2 Design Space 0.4 60.0-65.0
(non-linear)
50 1 0.2
0
600 40 42 44 46 48 50 52 54 56 58 60
Parameter 1
DOE SUMMARY
OFAT is an univariate approach: slow, inefficient,
assuming no interaction, leads to rigid manufacture
process with high risk of DP failure.
Thank You
DOE is a statistically designed multivariate approach.
DOE is an efficient tool to identify CPPs and CMAs and
establish relationship between CPP/CMA and CQA
Different DOEs are appropriate for different phases of
pharmaceutical development.
Use sound science, design space developed at lab or pilot
scale through DOE studies can be proposed for
commercial scale, but it needs to be verified at
production scale.
Overall, DOE is a valuable tool to facilitate the
implementation of QbD.